Dr Reddy's Scores US First With Generic Pataday Eye Drop Launch
Overview
Dr. Reddy's Laboratories has launched the first generic over-the-counter version of Pataday Extra Strength eye drops in the United States. Approved by the FDA, the olopatadine hydrochloride ophthalmic solution USP 0.7% expands the company's US eye-care portfolio, building on previous lower-strength offerings and leveraging its strength in store-brand equivalents.
Stocks Mentioned
Dr Reddy's Launches First Generic Pataday Eye Drops in US
Dr. Reddy's Laboratories Ltd announced on Wednesday, January 14, 2026, that it has successfully launched an over-the-counter (OTC) generic version of the Pataday Extra Strength eye drop in the United States. This marks a significant first for the Indian pharmaceutical major, positioning it as the inaugural company to market a generic version of this popular product.
First-to-Market Advantage
The newly launched product, sold as olopatadine hydrochloride ophthalmic solution USP 0.7%, has received approval from the U.S. Food and Drug Administration (FDA). It aims to provide temporary relief for itchy eyes caused by common allergens such as pollen and animal dander. Milan Kalawadia, CEO of North America Generics at Dr. Reddy's, emphasized the launch as a demonstration of the company's deep capabilities in developing store-brand equivalents for the U.S. market.
Portfolio Expansion
This strategic move significantly expands Dr. Reddy's existing U.S. OTC eye-care portfolio. The company already offers lower-strength versions of olopatadine at 0.1% and 0.2%. The introduction of the higher-strength, generic Pataday Extra Strength is expected to bolster its market presence and revenue streams in the U.S. eye-care segment. Dr. Reddy's aims to deepen its collaborations with retail customers through this key addition.
Market Performance
In a regulatory filing, the company highlighted the commercial success of its Pataday brand, noting that it recorded approximately $69.9 million in U.S. sales during 2025. Reflecting investor sentiment towards this development, shares of Dr. Reddy's Laboratories closed 0.02% higher on January 14, 2026, settling at ₹1,191.50 per share.
